Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech Buys QC Firm AcroMetrix

NEW YORK (GenomeWeb News) – Life Technologies said today that it has agreed to acquire AcroMetrix for an undisclosed amount.

AcroMetrix, based in Benicia, Calif., provides molecular and serological diagnostic quality control products to clinical laboratories, blood screening centers, and in vitro diagnostic manufacturers.

"With the growth of DNA- and other molecular-based tests, there is a growing need for high-quality, independently provided controls to ensure the accuracy and integrity of laboratory test results," Life Tech CEO Greg Lucier said in a statement.

Life Tech said that its molecular diagnostics product portfolio is responsible for some $300 million of the company's annual revenues, and includes technologies such as magnetic beads, fluorescent dyes, and antibodies; as well as products such as the SPOT-Light HER2 CISH kit for breast cancer; Dynachip system for automated HLA antibody screening; and various molecular diagnostic instruments.

"The acquisition of AcroMetrix builds on our substantial business of providing tools and technologies into the molecular diagnostics industry," Lucier added.

Life Tech said that the transaction is not expected to have a material effect on its financials in fiscal year 2010.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.